News

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...
I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed ...
ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...
Research led by Naval Medical University's Changzheng Hospital in China reports that an off-the-shelf cell therapy built from ...
Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are ...
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...